Last reviewed · How we verify

TNM001 — Competitive Intelligence Brief

TNM001 (TNM001) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Trispecific monoclonal antibody. Area: Oncology.

phase 3 Trispecific monoclonal antibody Oncology Biologic Live · refreshed every 30 min

Target snapshot

TNM001 (TNM001) — Zhuhai Trinomab Pharmaceutical Co., Ltd.. TNM001 is a trispecific antibody that simultaneously engages multiple immune checkpoints to enhance anti-tumor T-cell responses.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
TNM001 TARGET TNM001 Zhuhai Trinomab Pharmaceutical Co., Ltd. phase 3 Trispecific monoclonal antibody

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Trispecific monoclonal antibody class)

  1. Zhuhai Trinomab Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). TNM001 — Competitive Intelligence Brief. https://druglandscape.com/ci/tnm001. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: